Portland, OR, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The antihypertensive drugs industry was pegged at $22.56 billion in 2018, and is estimated to reach $28.79 billion by 2026, growing at a CAGR of 3.1% from 2019 to 2026. The report provides an extensive analysis of the market dynamics including drivers & restraints, major winning strategies, market size & projections, competitive landscape, and major segments.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/436
Increase in geriatric population worldwide, rise in healthcare expenditure worldwide, and surge in prevalence of hypertension across the globe have augmented the growth of the global antihypertensive drugs market. Whereas, patent expirations of blockbuster drugs impede the market growth. On the other hand, high growth potential in developing economies is projected to provide lucrative opportunities in the near future.
The global antihypertensive drugs market size is categorized on the basis of therapeutic class, distribution channel, and region. Based on drug class, the market is divided into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. The calcium channel blockers segment held the largest share in 2018, contributing to more than one-fourth of the global antihypertensive drugs market. However, the ACE inhibitors segment is projected to manifest the fastest CAGR of 4.7% during the forecast period.
Based on distribution channel, the market is categorized into retail pharmacy, hospital pharmacy, and e-commerce. The e-commerce websites and online drug stores segment is expected to register the fastest CAGR of 4.2% through 2026. On the other hand, the hospital pharmacy segment accounted for the highest share in 2018, contributing to more than half of the global antihypertensive drugs market.
The global antihypertensive drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The market across the North America region held the largest share in 2018, contributing to more than one-third of the revenue. However, the market across Asia Pacific is estimated to register the fastest CAGR of 4.2% during the forecast period.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/436
Key market players analyzed in the research include Merck KGaA, Takeda Pharmaceutical Co., Ltd., Johnson and Johnson, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Novartis International AG, AstraZeneca plc, Pfizer, Inc., Sanofi S.A., and Bayer AG.
Avenue Basic Plan | Library Access | 1 Year Subscription |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter
Get more information: https://www.alliedmarketresearch.com/library-access
Similar Reports:
Oncology/Cancer Drugs Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
HIV Drug Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Over the Counter (OTC) Drugs Market: Global Opportunity Analysis and Industry Forecast, 2017–2025
Ophthalmic Drugs Market: Global Opportunity Analysis and Industry Forecast, 2017–2025